NTLA Intellia Therapeutics Inc
Price (delayed)
$7.3
Market cap
$755.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.25
Enterprise value
$776.69M
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron.
Highlights
Intellia Therapeutics's revenue has surged by 60% YoY and by 34% QoQ
The gross profit has soared by 60% YoY and by 34% from the previous quarter
The company's debt has surged by 107% QoQ and by 82% YoY
The company's quick ratio fell by 33% YoY and by 13% QoQ
Key stats
What are the main financial stats of NTLA
Market
Valuations
Earnings
Shares outstanding
103.52M
Market cap
$755.68M
Enterprise value
$776.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.85
Price to sales (P/S)
12.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.42
Revenue
$57.88M
Gross profit
$57.88M
Operating income
-$534.26M
Net income
-$519.02M
EBIT
-$519.02M
EBITDA
-$508.74M
Free cash flow
-$354.66M
Per share
Balance sheet
Liquidity
EPS
-$5.25
EPS diluted
-$5.25
Free cash flow per share
-$3.59
Book value per share
$8.56
Revenue per share
$0.59
TBVPS
$12.05
Total assets
$1.19B
Total liabilities
$319.06M
Debt
$210.2M
Equity
$871.96M
Working capital
$529.01M
Debt to equity
0.24
Current ratio
5.77
Quick ratio
5.5
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
-879%
Gross margin
100%
Net margin
-896.8%
Operating margin
-923.1%
Return on assets
-43.1%
Return on equity
-54%
Return on invested capital
-48.1%
Return on capital employed
-48.1%
Return on sales
-896.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NTLA stock price
How has the Intellia Therapeutics stock price performed over time
Intraday
9.69%
1 week
-12.15%
1 month
-27.65%
1 year
-70.92%
YTD
-37.39%
QTD
2.67%
Financial performance
How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$57.88M
Gross profit
$57.88M
Operating income
-$534.26M
Net income
-$519.02M
Gross margin
100%
Net margin
-896.8%
Intellia Therapeutics's revenue has surged by 60% YoY and by 34% QoQ
The gross profit has soared by 60% YoY and by 34% from the previous quarter
Intellia Therapeutics's operating margin has increased by 35% YoY and by 26% QoQ
The company's net margin rose by 32% YoY and by 26% QoQ
Growth
What is Intellia Therapeutics's growth rate over time
Valuation
What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
0.85
P/S
12.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.42
The EPS has grown by 3.5% from the previous quarter and by 3.1% YoY
The stock's P/B is 85% below its 5-year quarterly average of 5.2 and 63% below its last 4 quarters average of 2.1
Intellia Therapeutics's equity has decreased by 17% YoY and by 9% from the previous quarter
The price to sales (P/S) is 88% lower than the 5-year quarterly average of 98.5 and 72% lower than the last 4 quarters average of 41.3
Intellia Therapeutics's revenue has surged by 60% YoY and by 34% QoQ
Efficiency
How efficient is Intellia Therapeutics business performance
The ROS has grown by 32% YoY and by 26% from the previous quarter
Intellia Therapeutics's ROE has decreased by 23% YoY and by 3.8% from the previous quarter
The ROA has contracted by 18% YoY
Intellia Therapeutics's ROIC has decreased by 12% YoY
Dividends
What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NTLA.
Financial health
How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has surged by 51% QoQ and by 27% YoY
The company's quick ratio fell by 33% YoY and by 13% QoQ
The company's debt is 76% lower than its equity
The debt to equity has soared by 118% from the previous quarter and by 118% YoY
The company's debt has surged by 107% QoQ and by 82% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.